Pure Global
NCT06386497

Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease

Overnight Treatment of Parkinson's Disease Using Vestibular Stimulation From a Rocking Bed (Somnomat Casa) - A Feasibility Study
Insel Gruppe AG, University Hospital Bern·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Parkinson Disease
Drug/Device/Intervention
Nocturnal translational vestibular stimulation
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Insel Gruppe AG, University Hospital Bern
Location
Bern,Zürich, Switzerland
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Dec 31, 2025
Enrollment
15 participants
Primary outcome

Evaluation of acceptability and feasibility,Evaluation of acceptability and feasibility

Summary

This pilot study aims to evaluate the feasibility and acceptability of nocturnal
 translational vestibular stimulations (VS) applied by a rocking bed (Somnomat Casa) for two
 months in patients with Parkinson's Disease.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismSecondary parkinsonism, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06386497
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06386497 through Pure Global AI's free database. This phase not specified trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.